Illumina (NASDAQ:ILMN) Stock Price Breaks Below 50 Day Moving Average Following Analyst Downgrade

Illumina, Inc. (NASDAQ:ILMN)’s share price passed below its 50 day moving average during trading on Friday after JPMorgan Chase & Co. lowered their price target on the stock from $320.00 to $300.00. The stock has a 50 day moving average of $249.30 and traded as low as $231.18. JPMorgan Chase & Co. currently has an overweight rating on the stock. Illumina shares last traded at $235.99, with a volume of 5,389,541 shares traded.

A number of other research firms have also issued reports on ILMN. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and raised their price target for the stock from $135.00 to $260.00 in a report on Wednesday, September 9th. Citigroup upped their price objective on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday, August 3rd. Argus increased their price objective on Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. Leerink Partners lifted their target price on Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. Finally, Stifel Nicolaus lifted their target price on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Nine equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and a consensus price target of $238.53.

Insider Transactions at Illumina

In related news, Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 2,061,235 shares of company stock worth $436,356,102 over the last three months. Corporate insiders own 2.90% of the company’s stock.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Hedge Funds Weigh In On Illumina

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Signature Equity Partners LLC boosted its holdings in Illumina by 246.5% during the third quarter. Signature Equity Partners LLC now owns 149 shares of the life sciences company’s stock worth $41,000 after buying an additional 106 shares in the last quarter. Fiduciary Financial Advisors purchased a new position in Illumina in the second quarter valued at about $26,000. MCF Advisors LLC increased its holdings in Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after buying an additional 100 shares in the last quarter. Keating Financial Advisory Services Inc. acquired a new stake in shares of Illumina during the 2nd quarter valued at approximately $32,000. Finally, Rakuten Securities Inc. acquired a new stake in shares of Illumina during the 2nd quarter valued at approximately $33,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

The company has a 50 day moving average price of $249.30 and a 200 day moving average price of $176.18. The firm has a market cap of $35.63 billion, a PE ratio of 40.62, a price-to-earnings-growth ratio of 4.11 and a beta of 1.41. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. Illumina had a return on equity of 29.41% and a net margin of 19.72%. The business had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same quarter in the prior year, the firm posted $1.34 EPS. The company’s revenue was up 4.2% compared to the same quarter last year. On average, sell-side analysts expect that Illumina, Inc. will post 5.36 EPS for the current year.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.